Literature DB >> 1261170

Pharmacokinetics of divided-dose ifosfamide.

R L Nelson, L M Allen, P J Creaven.   

Abstract

The pharmacokinetics of a divided-dose schedule of ifosfamide was investigated in 3 patients given 1, 600 to 2,400 mg/sq m/day for 3 days, with a second course of treatment 21 days later. In contrast to the biexponential decay seen with single-dose ifosfamide (5,000 mg/sq m), data for divided low-dose plasma ifosfamide are best fitted by a monoexponential decay function compatible with a one-compartment open model. Plasma half-life for ifosfamide given in the divided-dose schedule was 6.9 hr, less than half that previously reported for high single-dose ifosfamide. Renal excretion rates and clearances for unchanged drug were similar in both schedules. The proportion of drug metabolized was larger and amount of unchanged drug excreted in the urine was smaller than after single large doses. The elimination constant for unchanged ifosfamide increased from day 1 to day 2 of treatment and remained relatively stable from day 2 to day 3 in the multidose regimen, with all parameters reverting to the pretreatment values 21days later.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1261170     DOI: 10.1002/cpt1976193365

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

Authors:  T Kerbusch; A D Huitema; J Ouwerkerk; H J Keizer; R A Mathôt; J H Schellens; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

2.  The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

Authors:  L D Lewis; D L Fitzgerald; P Mohan; N Thatcher; P G Harper; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 3.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

5.  Metabolism and pharmacokinetics of oral and intravenous ifosfamide.

Authors:  V Kurowski; T Cerny; A Küpfer; T Wagner
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.

Authors:  T M Loeffler; F W Weber; T U Hausamen
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 7.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

8.  Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.

Authors:  V Gilard; M C Malet-Martino; M de Forni; U Niemeyer; J C Ader; R Martino
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Ifosfamide treatment as a 10-day continuous intravenous infusion.

Authors:  H J Keizer; J Ouwerkerk; K Welvaart; C J van der Velde; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.

Authors:  V Kurowski; T Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.